IL1B and COVID-19: Studies indicate that the potential activation of the NLRP3 inflammasome by SARS-CoV-2 directly leads to elevated levels of pro-inflammatory cytokines IL-1β and IL-18 in severe COVID-19 patients, which are associated with adverse outcomes (44).